Company intelligence / Profile preview

Crosshair Ventures

Sunnyvale, California, United Statesdnb.com ↗

Ownership: Private
Development stage: Other

Overview

Crosshair Therapeutics has developed a novel AI-powered D-Chains technology platform for designing chain-like peptide therapeutics that can precisely target hard-to-drug disease targets. The company has demonstrated proof of concept, established a production line for pre-clinical assets, and is advancing programs in oncology, neurology, and aging. No clinical trial results have been reported yet.

Therapeutic areas: NeurologyOncologyOther
Modalities: PeptidesGene therapy (AAV vector-based)Biologic (chain-like therapeutics)
Industry: Biotech

Beyond the preview

Go deeper on Crosshair Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crosshair Ventures.

Explore the full profile